Entheon Biomedical Corp. (ENBI.CN)
CAD 0.13
(8.33%)
CAD 0.13
(8.33%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -344.63 Thousand CAD | 49.33% |
| 2022 | -680.16 Thousand CAD | 66.81% |
| 2021 | -2.04 Million CAD | 26.48% |
| 2020 | -2.78 Million CAD | -146.76% |
| 2019 | -1.12 Million CAD | 7.76% |
| 2018 | -1.22 Million CAD | -281.6% |
| 2017 | -320.87 Thousand CAD | -1716.98% |
| 2016 | -17.66 Thousand CAD | 10.32% |
| 2015 | -19.69 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -299.13 Thousand CAD | -19.69% |
| 2024 Q3 | -228.59 Thousand CAD | 23.58% |
| 2024 Q1 | -249.92 Thousand CAD | 27.48% |
| 2023 FY | -344.63 Thousand CAD | 49.33% |
| 2023 Q2 | -478.56 Thousand CAD | 2.52% |
| 2023 Q1 | -490.91 Thousand CAD | 27.82% |
| 2023 Q4 | -344.63 Thousand CAD | 9.74% |
| 2023 Q3 | -381.8 Thousand CAD | 20.22% |
| 2022 Q2 | -167.58 Thousand CAD | 79.6% |
| 2022 Q3 | -248.38 Thousand CAD | -48.22% |
| 2022 FY | -680.16 Thousand CAD | 66.81% |
| 2022 Q1 | -821.32 Thousand CAD | 59.92% |
| 2022 Q4 | -680.16 Thousand CAD | -173.84% |
| 2021 Q2 | -4.1 Million CAD | 18.22% |
| 2021 FY | -2.04 Million CAD | 26.48% |
| 2021 Q1 | -5.02 Million CAD | -80.2% |
| 2021 Q4 | -2.04 Million CAD | 39.43% |
| 2021 Q3 | -3.38 Million CAD | 17.63% |
| 2020 FY | -2.78 Million CAD | -146.76% |
| 2020 Q4 | -2.78 Million CAD | -184.14% |
| 2020 Q2 | -1.06 Million CAD | 5.75% |
| 2020 Q1 | -1.13 Million CAD | 8.23% |
| 2020 Q3 | -980.84 Thousand CAD | 8.11% |
| 2019 Q2 | -1.14 Million CAD | 6.22% |
| 2019 FY | -1.12 Million CAD | 7.76% |
| 2019 Q4 | -1.23 Million CAD | -6.46% |
| 2019 Q3 | -1.15 Million CAD | -0.95% |
| 2019 Q1 | -1.22 Million CAD | -34.05% |
| 2018 Q2 | -1.27 Million CAD | -297.23% |
| 2018 Q3 | -848.96 Thousand CAD | 33.4% |
| 2018 Q4 | -913.43 Thousand CAD | -7.59% |
| 2018 Q1 | -320.87 Thousand CAD | 0.0% |
| 2018 FY | -1.22 Million CAD | -281.6% |
| 2017 FY | -320.87 Thousand CAD | -1716.98% |
| 2016 FY | -17.66 Thousand CAD | 10.32% |
| 2015 FY | -19.69 Thousand CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | -125.08 Thousand CAD | -175.519% |
| Asep Medical Holdings Inc | -44.72 Thousand CAD | -670.629% |
| BetterLife Pharma Inc. | 207.85 Thousand CAD | 265.809% |
| BioVaxys Technology Corp. | -977.00 CAD | -35174.616% |
| ChitogenX Inc. | 3.84 Million CAD | 108.975% |
| Rapid Dose Therapeutics Corp. | 2.29 Million CAD | 115.032% |
| Defence Therapeutics Inc. | 1.68 Million CAD | 120.394% |
| Gemina Laboratories Ltd. | 284.33 Thousand CAD | 221.206% |
| Glow Lifetech Corp. | 116.15 Thousand CAD | 396.714% |
| Lexston Life Sciences Corp. | -390.4 Thousand CAD | 11.724% |
| Pharmala Biotech Holdings Inc. | 58.49 Thousand CAD | 689.167% |
| Doseology Sciences Inc. | -1.06 Million CAD | 67.494% |
| MYND Life Sciences Inc. | 2.99 Million CAD | 111.489% |
| Nova Mentis Life Science Corp. | -8088.00 CAD | -4161.041% |
| PharmaTher Holdings Ltd. | -2.13 Million CAD | 83.845% |
| PreveCeutical Medical Inc. | 3.83 Million CAD | 108.992% |
| Telescope Innovations Corp. | -719.49 Thousand CAD | 52.101% |